MedTrace Logo

Intravenous Tranexamic Acid Versus IV Carbetocin in Abdominal Myomectomy

NCT04357015 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2020-04-22

No results posted yet for this study

Summary

the aim of the present study is to compare safety and efficacy of intravenous tranexamic acid versus IV carbetocin in reducing blood loss during abdominal myomectomy: a randomized controlled trial

Conditions

  • Myomectomy

Interventions

DRUG

intravenous tranexamic acid

The tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision

DRUG

intravenous carbetocin

The carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision

DRUG

placebo

the placebo group will be given a normal saline IV bolus 20 minutes before surgical incision

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2020-10-10
Completion
2020-10-20

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04357015 on ClinicalTrials.gov